This article was originally published on Microdose Psychedelic Insights and appears here with permission.
The renowned Icahn School of Medicine at Mount Sinai Health Systems has launched the Center for Psychedelic Psychotherapy and Trauma Research. Psychedelic science and research have been the cornerstone of its modern renaissance and this move follows on the heels of other leading academic institutions establishing similar centers, such as the Johns Hopkins Center for Psychedelic Research. This cutting-edge research institution will take a multipronged “clinical and research approach to discovering novel and more efficacious therapies for post-traumatic stress disorder (PTSD), depression, anxiety, and other stress-related conditions in the veteran and civilian population.” The Center is focusing their efforts on studying the effects of MDMA, psilocybin, and other psychedelic compounds in the treatment of difficult to treat mental health concerns.
Psychedelics Have Already Shown Promising Efficacy in Mental Illness Treatment
Currently, both psilocybin and MDMA are being expedited through clinical trials in the United States after being granted “breakthrough therapy” status by the FDA. Studies have shown MDMA is remarkably effective in the treatment of PTSD, a condition currently lacking any genuinely effective pharmacological interventions. Additionally, psilocybin has shown incredible efficacy in helping patients with treatment-resistant depression and addiction, both severely underserved populations. As these clinical trials expand in size and scope, centers such Mount …